load

New indications in otorhinolaryngology for one of the most prominent antibacterial drug

New indications in otorhinolaryngology for one of the most prominent antibacterial drug

10.12.2018

Valenta Pharm completed a large-scale comprehensive study of use of the antibacterial drug Dioxidin® for the treatment of infectious and inflammatory diseases of ENT organs, which resulted in new indications registered in November 2018.

The Ministry of Health of the Russian Federation has approved the following indications for the medical use of Dioxidin®: acute purulent perforative otitis media, exacerbation of chronic suppurative otitis media, acute tonsillopharyngitis, exacerbation of chronic tonsillitis (compensated form)1. The registration of the Dioxidin® indications open up new horizons in the treatment of infectious inflammatory ENT diseases.

Valery Mikhailovich Svistushkin, Dr. habil. med., professor, M.D. Board certified, Clinic Director, Head of the ENT Department, I.M. Sechenov First Moscow State Medical University State Medical University. THEM. Sechenov, senior external otolaryngologist of the Central Federal District of the Russian Federation, said: “Antibiotics and antibacterial drugs make up at least half of the daily ENT doctor's prescriptions. But the possibilities of antibiotics are not limitless, and the adaptation strength of microorganisms is so great that antibiotic resistance is a planetary-scale threat. Therefore, we, practicing otorhinolaryngologists, should not forget that antibacterial drugs should not only help here and now, but most importantly should not benefit to an increase in resistance and the formation of new antibiotic-resistant strains of bacteria. Registration of ENT indications for a drug as well-known as Dioxidin® certainly opens up new possibilities. An important feature of Dioxidin is its activity against the absolute majority of ENT pathogens, including those resistant to antibiotics.”

Dioxidin® is an original broad-spectrum antibacterial drug intended for the local treatment of purulent infections. Due to its three-step mechanism of bactericidal action, Dioxidin® has a low risk of developing resistance. Microbiological efficacy of the drug Dioxidin covers 93% of the studied bacterial strains, including those resistant to antibiotics and antiseptics.

The drug is available on prescription only.

  • 1Medication Guidelines (Р N003934/01).